Debulking nephrectomy followed by a "watch and wait" approach in metastatic renal cell carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 27, Issue 2, 2009, Pages 149-154

  Wong, Alvin S ^a   Chong, Kian Tai ^b   Heng, Chin Tiong ^b   Consigliere, David T ^a   Esuvaranathan, Kesavan ^a   Toh, Khai Lee ^b   Chuah, Benjamin ^a   Lim, Robert ^a   Tan, James ^b  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

Debulking nephrectomy; Metastatic; Renal cell carcinoma; Watch and wait

Indexed keywords

ANTINEOPLASTIC AGENT; INTERFERON; THALIDOMIDE;

ADULT; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; LABORATORY TEST; MALE; NEPHRECTOMY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEPHRECTOMY; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; UROLOGY;

EID: 61649105553     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2007.10.017     Document Type: Article

References (31)

1. Flanigan R.C., Salmon S.E., Blumenstein B.A., et al. Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal cell cancer. N Engl J Med 345 (2001) 1655-1659
2. Mickish G.H., Garin A., van Poppel H., et al., European Organization for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon-α alone in metastatic renal cell carcinoma: A randomized trial. Lancet 358 (2001) 966-970
3. Tannock I. Commentary on "Cytoreduction nephrectomy in metastatic renal cancer: The results of SWOG trial 8949". J Clin Oncol 18 (2000) 39s-42s
4. Tannock I. Removing the cancer after the tumor has spread. N Engl J Med 345 (2001) 1699-1700
5. Pyrhonen S., Salminen E., Ruutu M., et al. Prospective randomized trials of interferon α-2a plus vinblastine vs. vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17 (1999) 2859-2867
6. Medical Research Council Renal Cancer Collaborators. Interferon-α and survival in metastatic renal cell carcinoma: Early results of a randomized controlled trial. Lancet 353 (1999) 14-17
7. Messing E.M., Manola J., Wilding G., et al. Phase III study of interferon α-NL as adjuvant treatment for resectable renal cell carcinoma: An Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 21 (2003) 1214-1222
8. Trask P.C., Esper P., Riba M., et al. Psychiatric side effects of interferon therapy: Prevalence, proposed mechanisms and future directions. J Clin Oncol 18 (2000) 23316-23326
9. Hancock B., Griffiths G., Ritchie A., et al. Updated results of the MRC randomized controlled trial of α interferon vs. MPA in patients with metastatic renal cancer. Proceedings of the 2000 ASCO Annual Meeting 19 (2000) 340a [Abstract]
10. Van Poppel H., and Baert L. Nephrectomy for metastatic renal cell carcinoma and surgery for distant metastases. Acta Urol Belg 64 (1996) 11-17
11. Motzer R.J., Mazumdar M., Bacik J., et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17 (1999) 2530-2540
12. Eisenberg M.S., Meng M.V., Master V.A., et al. Laparoscopic versus open cytoreductive nephrectomy in advanced renal cell carcinoma. J Endourol 20 (2006) 504-508
13. Rabets J.C., Kaouk J., Fergany A., et al. Laparoscopic vs. open cytoreductive nephrectomy for metastatic renal cell carcinoma. Urology 64 (2004) 930-934
14. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib vs. interferon-α in metastatic renal cell carcinoma. N Engl J Med 356 (2007) 115-124
15. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear cell renal cell carcinoma. N Engl J Med 356 (2007) 125-134
16. Mulder S.F., Spronsen D.J., and Mulder P.H. Do the results of the new trials change the standard treatment of metastatic renal cell cancer?. Onkologie 30 (2007) 260-264
17. Oliver R.T., Miller R.M., Mehta A., et al. A Phase 2 study of surveillance in patients with metastatic renal cell carcinoma and assessment of response of such patients to therapy on progression. Mol Biother 1 (1988) 14-20
18. Gleave M.E., Elhilali M., Fradet Y., et al. Interferon γ-1b compared with placebo in metastatic renal cell carcinoma. Canadian Urology Oncology Group. N Engl J Med 338 (1998) 1265-1271
19. Eggener S.E., Yossepowitch O., Pettus J.A., et al. Renal cell carcinoma recurrence after nephrectomy for localized disease: Predicting survival from time of recurrence. J Clin Oncol 24 (2006) 3101-3106
20. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon-α, or both for advanced renal cell carcinoma. N Engl J Med 356 (2007) 2271-2281
21. Cheville J.C., Lohse C.M., Zincke H., et al. Sarcomatoid renal cell carcinoma: An examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol 28 (2004) 435-441
22. Ramsey S., Lamb G.W., Aitchison M., et al. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 109 (2007) 205-212
23. Donskov F., and von der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 1997-2005
24. Rini B.I. Current status and future directions of molecular markers in renal cell carcinoma. Curr Opin Urol 16 (2006) 332-336
25. Kosari F., Parker A.S., Kube D.M., et al. Clear cell renal cell carcinoma: Gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res 11 (2005) 5128-5139
26. Bukowski R.M., Negrier S., and Elson P. Prognostic factors in patients with advanced renal cell carcinoma: Development of an international kidney cancer working group. Clin Cancer Res 10 (2004) 6310S-6314S
27. Collins S., Pierorazio P.M., McKiernan J.M., et al. Fractional percentage of tumor volume removed is a predictor of outcome following cytoreductive nephrectomy for metastatic renal cell carcinoma. Proceedings of the 2006 ASCO Annual Meeting Part I. J Clin Oncol 24 Suppl (2006) 4599
28. Rasco D.W., Assikis V., and Marshall F. Integrating metastasectomy in the management of advanced urological malignancies-where are we in 2005?. J Urol 176 (2006) 1921-1926
29. Vogl U.M., Zehetgruber H., Dominkus M., et al. Prognostic factors in metastatic renal cell carcinoma: Metastasectomy as independent prognostic variable. Br J Cancer 95 (2006) 691-698
30. Walther M.M., Yang J.C., Pass H.I., et al. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol 158 (1997) 1675-1678
31. Olivier C., Carballido J., Lao A.H., et al. The surgical opportunity in metastatic lesions of renal cell carcinoma after a response to adjuvant immunotherapy. Acta Urol Esp 19 (1995) 203-210